Mitchell H. Gold, M.D., has been elected to the Board of Trustees of the nonprofit Cancer Research Institute. Dr. Gold is chairman, chief executive officer, and founder of Alpine Biosciences, a privately held, Seattle-based biotech company dedicated to developing the next generation of cancer immunotherapies
MedImmune, the global biologics arm of AstraZeneca, has signed a collaboration with two nonprofits, the Cancer Research Institute and Ludwig Institute for Cancer Research, to advance clinical development of cancer immunotherapy
Nonprofit pioneer in tumor immunology names recipients of 2012 scientific and lay awards celebrating outstanding contributions to advancing cancer immunotherapy.
Cancer Research Institute, Inc. announced today that it has committed more than $10 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development at research centers worldwide.
The Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the discovery and development of safe and effective immunotherapies for cancer, today announced the relaunch of the open access, online journal Cancer Immunity, the official journal of the Cancer Research Institute.
New York City's business, political, media, and philanthropy elite gathered at The Four Seasons restaurant for the "Through the Kitchen" benefit for the Cancer Research Institute, raising a record $914,000 to support cancer immunology postdoctoral research fellowships.
Cancer Research Institute awarded top score from charity ratings service Charity Navigator.
Cancer Research Institute, the leader in advancing the field of cancer immunology, and Stand Up To Cancer have partnered to fund the SU2C-CRI Cancer Immunology Translational Research Dream Team
11 young scientists working in cancer immunology receive prestigious postdoctoral fellowship award from the Cancer Research Institute
The Cancer Research Institute (CRI), a U.S. nonprofit organization dedicated to transforming cancer patient care by supporting and coordinating global research in tumor immunology, announced today that CRI founding scientific and medical director Lloyd J. Old, M.D., regarded as the “Father of Modern Tumor Immunology,” died early this morning at his home in New York City from prostate cancer. He was 78 years old.
Joint paper published in Science Translational Medicine by two cancer immunotherapy associations describes recent results of international, cross-laboratory immune assay harmonization studies, and guides the improvement of immune response measurements in early clinical studies of cancer immunotherapies.
Leading international association of cancer immunotherapy developers, the Cancer Immunotherapy Consortium, appoints James P. Allison, Ph.D., and Axel Hoos, M.D., Ph.D., as co-directors.
Scientists and leaders from industry and philanthropy honored for outstanding contributions to cancer immunotherapy at Oct. 3 Cancer Research Institute gala in New York City.
Nature Biotechnology published joint white paper of the CRI Cancer Immunotherapy Consortium (CIC) and the Association for Cancer Immunotherapy (CIMT) outlining a comprehensive framework to enhance clinical development of cancer immunotherapies.
The three winners of the 2011 Nobel Prize in Physiology or Medicine are members of the Cancer Research Institute community who have received past CRI support and recognition for their scientific contributions.
James P. Allison, Ph.D., has been named to succeed Lloyd J. Old, M.D., as director of the Cancer Research Institute Scientific Advisory Council.
The Cancer Vaccine Collaborative (CVC), a joint initiative of the Cancer Research Institute and the Ludwig Institute for Cancer Research, and the first academic network dedicated to the development of effective therapeutic cancer vaccines, has named Jedd D. Wolchok, M.D., Ph.D., as the new CVC director and has expanded its leadership to include seven additional experts in cancer immunotherapy research.
Former CRI Postdoctoral Fellow Stephen C. Jameson will receive the 2011 Frederick W. Alt Award for New Discoveries in Immunology from the Cancer Research Institute at the 25th Annual CRI Awards Dinner, October 3, 2011, in New York City.
Philip D. Greenberg and Steven A. Rosenberg, pioneers is adoptive T cell transfer therapy for cancer, will receive 2011 William B. Coley Award at 25th Annual Awards Dinner Gala in NYC on October 3, 2011.
Cancer Research Institute will give the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research to Mitchell H. Gold, president and CEO of Dendreon Corporation, to celebrate the FDA approval of the company's prostate cancer vaccine, Provenge, the first FDA-approved therapeutic cancer vaccine
Non-profit funder of cancer immunology research launches new programs to signal start of next phase in organization's mission to bring safe and effective immune system-based therapies to cancer patients sooner.
Cancer Research Institute announces $9.7 million in research funding for academic scientists in the fields of immunology and tumor immunology.
Hollywood producer and cancer activist Laura Ziskin Dies of breast cancer. Cancer Research Institute to posthumously award Ziskin the 2011 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.
Through The Kitchen is a themed benefit for the Irvington Institute Fellowship Program of the Cancer Research Institute, which supports young scientists in immunology and tumor immunology.
Three CRI scientists describe in this latest issue of Science magazine immunity’s paradoxical role in the promotion and control of cancer, a new understanding that places new treatments like ipilimumab (Yervoy) and sipuleucel-T (Provenge) within the context of 100 years of progress in tumor immunology and cancer immunotherapy.
Yervoy (ipilimumab), a monoclonal antibody, received FDA approval today to treat advanced melanoma. This first-in-class antibody drug may also significantly improve standard cancer treatments.
The Cancer Immunotherapy Consortium (CIC), a program of the nonprofit Cancer Research Institute, will host its 2011 Scientific Colloquium March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD. This year’s meeting, titled “Schedule and Dose for Combination Therapy,” will include a series of plenary lectures from academic and industry leaders in tumor immunology and immunotherapy.
Cancer Research Institute, a nonprofit organization, has awarded $450,000 to Oncovir, Inc., to Produce and Supply Hiltonol® (Poly-ICLC) for Use in Clinical Trials of Cancer Vaccines and Other Immunotherapies.
New model of venture philanthropy aims to improve cancer patient care sooner by speeding development of highly promising cancer immunotherapies.
Joint position paper by U.S. and European immunologists describing an international collaborative effort to arrive at minimal reporting requirements for T cell-based immune monitoring assays
Cancer Research Institute scientists recommend modifications to the clinical development paradigm to improve evaluation of immuotherapies for cancer.
Cancer Research Institute, Inc. (CRI), celebrates yesterday’s announcement from the Medical Research Council that Vincenzo Cerundolo, M.D., Ph.D., has been named director of the MRC Human Immunology Unit (HIU) at the John Radcliffe Hospital in Oxford, U.K.
First treatment ever proven in a randomized trial to extend life for patients whose melanomas are unresponsive to existing cancer therapies.
The Cancer Research Institute bestows the 2010 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology upon three outstanding scientists at its upcoming 24th Annual Awards Dinner, to be held June 16, 2010, in New York City.
Tumor immunologists are hailing the first FDA approval of a therapeutic cancer vaccine as a milestone victory, but many experts agree more research is needed to optimize cancer vaccines.
The 28th Annual "Through the Kitchen" Party at The Four Seasons Restaurant in New York City will take place Sunday, April 25, 2010. Proceeds benefit the Irvington Fellowship Program of the Cancer Research Institute.
A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.
The Cancer Research Institute (CRI), a U.S.-based nonprofit organization that supports and coordinates laboratory and clinical efforts to harness the disease-fighting power of the immune system to treat, control, and prevent cancer, announced today that its program, the Cancer Vaccine Consortium—a leading global initiative on cancer vaccine research and development comprising industry, academia, and government institutions—has changed its name to the Cancer Immunotherapy Consortium (CIC).
Fashion Designer Michael Kors and GlaxoSmithKline Head Andrew Witty to Receive the 2010 Oliver R. Grace Award from the Cancer Research Institute (CRI) during CRI's 24th Annual Awards Dinner to be held June 16, 2010, at the Mandarin Oriental in New York City.
Cancer researchers have taken a major step forward toward what is planned to be the most comprehensive analysis of the body’s antibody response to human cancer, an enterprise that has been termed “cancer seromics.”
The laboratory of Dr. Lloyd J. Old of the Ludwig Institute for Cancer Research (LICR), together with Dr. Yao-Tseng Chen at Weill Cornell Medical College and their collaborators, made the finding that CT45, a cancer/testis (CT) antigen normally expressed in testicular germ cells in both prenatal and adult life, is expressed by the Reed-Sternberg cells in most of the classical Hodgkin lymphomas. The finding has implications for diagnostic, prognostic, and therapeutic approaches for Hodgkin lymphoma.
Young philanthropists ages 21-40 gather on March 25, 2010, at Saks Fifth Avenue in NYC to raise funds for the Cancer Research Institute. Spring 2010 fashions on display, silent auction, and other prizes.
A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.
The Cancer Research Institute (CRI) and the Association for Cancer Immunotherapy (CIMT) announce the launch of a global, broad-based initiative to improve the reliability of reports of data derived from T cell-based immune monitoring assays, especially those used in the study of therapeutic vaccines for cancer and infectious diseases.
The Cancer Research Institute, Inc. (CRI) has announced that Anjana Rao, Ph.D., professor of pathology at the Harvard Medical School in Boston, MA, is the winner of the Cancer Research Institute 2009 Frederick W. Alt Award for New Discoveries in Immunology.
Cancer vaccine researchers and immunologists from academia and industry will meet for three days in New York City at a Cancer Research Institute symposium, "Control of Cancer Immunosuppression: The Challenge for Cancer Vaccine Development."
The Stenbeck Foundation, a family foundation established in 2008 by the heirs of Swedish industrialist Jan Stenbeck, has made a generous gift of $1 million to the Cancer Research Institute (CRI) to support the Institute’s ovarian cancer research efforts.
The first batch of NY-ESO-1 recombinant protein produced in a facility supported entirely by non-profit entities has successfully cleared regulatory review and has entered clinical testing. The clinical trials are part of the Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd. (LICR).
Even in a tight economy, young people in their 20s and 30s will still give to important charitable causes. More than 320 such "young philanthropists" turned out for a Cancer Research Institute benefit at one of Manhattan's premiere nightclubs on August 6, 2009.
The FDA announced on Aug 4 2009 that tumor necrosis factor (TNF) blockers used in the treatment of immune disorders carry an increased risk of lymphoma and other cancers in children and adolescents. The discoverer of TNF-alpha, Lloyd J. Old, M.D., a tumor immunologist, is available for comment.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right